Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Eris Lifesciences has informed that the Board of Directors of the Company, in its meeting held today, i.e., 14th March, 2024, duly approved/ took on record the following: Agreement to acquire the Branded Formulations businesses of Biocon Biologics pertaining to the Indian Territory to the extent and in the manner mentioned therein; Agreement to acquire 19% equity stake in Swiss Parenterals from the Promoters of the Company. In compliance with the SEBI Circular dated July 13, 2023 bearing reference number SEBI/HO/CFD/CFDPoD1/P/CIR/2023/123, the additional details given under the attached Annexures. The meeting of the Board of Directors commenced at 11:30 AM and concluded at 03:05 PM.
The above information is a part of company’s filings submitted to BSE.
